Journal Mobile

Author(s): 
KS Lyons, M Harbinson
Journal Issue: 
Volume 39: Issue 4: 2009

Format

Abstract

 

Since  the  first  human  trial  of  a  hydroxymethylglutaryl-coenzyme  A (HMG  CoA)  reductase  inhibitor  in  1978,  the  growth  in  importance  of  this  drug class, both financially and medically, has been staggering. The aim of this paper is to summarise how this drug class was developed, highlighting the role of Akira Endo.

PDF